The generic products company had challenged the patent and secured a six-month exclusive right to sell a low-cost version of the $10.7 billion medicine in the US market after the expiry.
A leading exporter said, there is enough stock of paracetamol in the country. At present, the US, which has become the epicentre of the COVID-19 outbreak, needs paracetamol. He further said India would lose its credibility as the "pharmacy of the world" if it adopts protectionist policies during such a crisis.
Indian equities are no longer cheap vis-a-vis global markets, and only a short distance away from being the most expensive they have ever been.
The anti-depressant drug market in the US is primarily ruled by Effexor XR (Venlafaxine) of Wyeth (now owned by Pfizer).
Its factory in Chikalthana in western India was last month hit by the British drug regulator's curb on imports from the plant over manufacturing deficiencies.
According to analysts, Glenmark will have to pay a penalty of $16 million, following the latest verdict.
Sun Pharmaceutical Industries said it has received approval from US health regulator to market generic Clarinex tablets and Tiazac capsules, used in treating nasal allergies and hypertension, respectively, in the American market.
Ranbaxy Laboratories, Dr Reddy's Laboratories and Sun Pharma's US subsidiary Caraco Pharmaceuticals are among the 13 generic manufacturers to get first generic approvals from the US Food and Drug Administration to manufacture and market generic versi
FDI in drugs and pharmaceuticals was $487 million during April-August 2012, according to the latest data of the Department of Industrial Policy and Promotion.
Cipla has agreed to buy two generics businesses in the United States in an all-cash deal worth $550 million.
The US Drug maker requested the court to pass an order to restrain DRL from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing DRL's generic paricalcitol injectable products prior to the expiration of said patents.
Not too long ago, authorised generics were used by the big US-based pharmaceutical companies to thwart competition from makers of generic drugs
India has airlifted more than 6 million COVID-19 doses to nine countries in Phase-I under its initiative termed "Vaccine Maitri".
'The obvious opportunity is biosimilars, which are simpler but more expensive,' says Kiran Mazumdar-Shaw, founder of Biocon.
Earlier in April, Sun Pharmaceuticals Industries announced acquisition of Ranbaxy in an all-share deal.
The Department of Industrial Policy and Promotion in its draft Cabinet has proposed to further tighten the rules for foreign direct investment in brownfield pharmaceutical sector.
Over 550,000 small drug retailers in the country are transforming into producers and marketers of pharmaceutical products, readying to compete with companies such as Ranbaxy, Cipla, Sun Pharma and Lupin whose produce they sell.
'We have to rise over our divisions.' 'Divisions within us allow unscrupulous politicians to divert attention from issues like corruption and governance.'
The Indian major is eyeing German Merck's generic drug business.
India and Brazil raised a trade dispute against the European Union before the World Trade Organization on Tuesday over seizure of generic drugs by EU member countries on high seas.
The growth prospects are particularly high for Indian companies in the speciality and complex generic drugs segment in the US, the report said.
Regulators tighten net on safety grounds.
In his press conference on Wednesday, Trump targeted drug-makers and vowed to bring back production in the US.
The Indian Medical Association and the Mumbai Association of Medical Consultant have written a letter to Narendra Modi expressing disappointment over his statement during the Bharat ki Baat Sabke saath event in London.
Calling the FIR against the army as 'unfortunate', Lt Gen Anbu said that there should have been generic FIR in the matter.
.jpg)
After a high-level meeting held on Friday chaired by Prime Minister Manmohan Singh, it has been decided that the Commerce and Industry would soon start a consultation process to address 'dangers inherent' in the current model of FDI in brownfield pharma units.
US firm Mylan NV received a stern warning from the FDA in August for faulty manufacturing practices at three of its India drugmaking plants.
Zydus Pharmaceuticals Inc, the US arm of Zydus Cadila has entered into a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a business unit of Tyco Healthcare to market generic products in the US.
Drug firm Strides Acrolab on Tuesday said it is in a position to supply Oseltamivir Capsules, the only available medicine against Influenza A HINI virus (Swine Flu), to meet the demand both from domestic and overseas market.
US District Judge Beryl Howell in Minneapolis denied Ranbaxy's request, the court filing showed.
The government plans to rationalise trade margins for many other medical devices, besides stents and knee implants.
This acquisition marks Lupin's foray into the Japanese branded market in-line with aspirations to build business globally.
At any time, there is a need to operationally deploy two aircraft carriers in the vast Indian Ocean, asserts Vice Admiral Premvir Das (retd).
China is on the lookout for investment pastures where its money is welcome, safe and earns a decent return. India also needs vast investment - about $1 trillion over the next 10-15 years - in infrastructure, green energy, transportation and heavy industry, says Ravi Bhoothalingam.
Indian firm to soon launch copycat of anti-breast-cancer drug.
Sayre Therapeutics aims for a spot among top 5 players in oncology.
'The reality of this virus is that as long as it is circulating, it can mutate into new variants and by the time you realise that this is a new virus, which is more dangerous, and more transmissible, it is too late.'
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances